Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology
https://doi.org/10.20996/1819-6446-2019-15-2-251-257
Abstract
A recently published article [1 ] on the problems of anticoagulant therapy in patients with frailty syndrome contains two statements which highlight ri-varoxaban among other non-vitamin K antagonist oral anticoagulants (NOAC): 1) none of the randomized controlled trials (RCTs) with NOAC (except for two RCTs with rivaroxaban - EINSTEIN-DVT and EINSTEIN-PE) contained data on the participation of frail patients; 2) one of the studies of real clinical practice showed that only therapy with rivaroxaban (out of three NOAC) in comparison to warfarin reduced the risk of stroke/systemic embolism and ischemic stroke in frail elderly patients with atrial fibrillation after 2 years of observation. The paper presents a critical analysis of these statements showing that the first statement is based on the incorrect use of the collective term "fragility” as a synonym for the term "frailty”, whereas the second statement is based on the results of a study that has a number of serious methodological limitations.
About the Authors
S. N. Bel'diev
Tver State Medical University
Russian Federation
Russian Federation
Sergey N. Bel'diev - MD, PhD, Associate Professor, Chair of Therapy and Cardiology.
Sovetskaya ul. 4, Tver, 170100I. V. Medvedeva
Tver State Medical University
Russian Federation
Russian Federation
Irina V Medvedeva - MD, PhD, Associate Professor, Chair of Therapy and Cardiology.
Sovetskaya ul. 4, Tver, 170100D. Yu. Platonov
Tver State Medical University
Russian Federation
Russian Federation
Dmitry Yu. Platonov - MD, PhD, MPH, Associate Professor, Head of Chair of Therapy and Cardiology.
Sovetskaya ul. 4, Tver, 170100
G. Yu. Trufanova
Tver State Medical University
Russian Federation
Russian Federation
Galina Yu. Trufanova - MD, PhD, Associate Professor, Chair of Therapy and Cardiology.
Sovetskaya ul. 4, Tver, 170100
References
1. Vorobyeva N.M., Tkacheva O.N. Anticoagulant therapy in "fragile" elderly patients: current state of the problem. Rational Pharmacotherapy in Cardiology. 2018;14(6):908-1 6 (In Russ.) doi:10.20996/1819-6446-2018-14-6-908-916.
2. Buller H.R., Prins M.H., Lensin A.W. et al. EINSTEIN-PE Investigators. Oral rivaroxabanfor the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1 287-97. doi:10.1056/NEJ-Moa1113572.
3. Prins M.H., Lensing A.W., Bauersachs R. et al. EINSTEIN Investigators. Oral riva roxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EIN-STEIN-DVTand PE randomized studies. Thromb J. 2013;11 (1 ):21. doi:10.1186/1477-9560-11-21.
4. Fried L.P., Tangen C.M., Walston J. et al. Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001 ;56(3):M146-56. doi:10.1093/gerona/56.3.m146.
5. Searle S.D., Mitnitski A., Gahbauer E.A. et al. A standard procedure for creating a frailty index. BMC Geriatr. 2008;8:24. doi:10.1186/1471-2318-8-24.
6. Bel'diev S.N., Platonov D.Ju. A typical mistake in prescribing riva roxaban to elderly patients with atrial fibrillation. Russian Heart Journal. 2017;1 6(3):207-1 2 (In Russ.) doi:10.18087/rhj.2017.3.2345.
7. Halvorsen S., Atar D., Yang H. et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014;35(28):1864-72. doi:10.1093/eurheartj/ehu046.
8. Eikelboom J.W., Wallentin L., Connolly S.J. et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011 ;1 23(21 ):2363-72. doi:10.1161/CIRCULATIONAHA.110.004747.
9. Halperin J.L., Hankey G.J., Wojdyla D.M. et al. Efficacy and safety of riva roxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Riva roxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014;130(2):1 38-46. doi:10.1161/CIRCULA-TIONAHA.113.005008.
10. Lauw M.N., Eikelboom J.W., Coppens M. et al. Effects of dabigatran according to age in atrial fibrillation. Heart. 2017;1 03(1 3):1 01 5-23. doi:10.1136/heartjnl-2016-310358.
11. Martinez B.K., Sood N.A., Bunz TJ., Coleman C.I. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in frail patients with nonvalvular atrial fibrillation. J Am Heart Assoc. 2018;7(8):e008643. doi:10.1161/JAHA.118.008643.
12. Martsevich S.Yu., Kutishenko N.P. Randomized clinical trials and observational studies: the ratio in the hierarchy of evidence of the efficacy of drugs. Rational Pharmacotherapy in Cardiology. 2016;1 2(5):567-73 (In Russ.) doi:10.20996/1819-6446-2016-12-5-567-573.
13. Martsevich S.Yu., Lukina YV., Kutishenko N.P. Once again about the hierarchy of evidences in medicine or whether it is possible to choose the most effective and safe drug with the help of observational studies. Rational Pharmacotherapy in Cardiology. 2017;13(2):270-4 (In Russ.) doi:10.20996/1819-6446-2017-13-2-270-274.
14. Arutyunov G.P., Arhipov M.V., Bakalov I.N. et al. Place and significance of observational studies of NOACs in patients with non-valvular atrial fibrillation from the standpoint of evidence-based medicine. Russian Heart Journal. 2016;15(6):441 -7 (In Russ.) doi:10.18087/rhj.2016.6.2297.
15. US Food and Drug Administration. Pradaxa (dabigatran etexilate mesylate): full prescribing information. [cited by Mar 03, 201 8]. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022512s035lbl.pdf.
16. The State Register of Medical Products. Pradaxa prescribing information [cited by Mar 03, 201 8]. Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=bb76178c-cf95-4cbd-9883-6ba08ccb508d&t=. (In Russ.)
17. Coleman C.I., Turpie A., Bunz TJ, Sood N. Effectiveness and safety of apixaban, dabigatran and ri-varoxaban versus warfarin in frail patients with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2018;71 (S11):A290. doi:10.1016/S0735-1097(18)30831-3.
Review
For citations:
Bel'diev S.N., Medvedeva I.V., Platonov D.Yu., Trufanova G.Yu. Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology. Rational Pharmacotherapy in Cardiology. 2019;15(2):251-257. (In Russ.) https://doi.org/10.20996/1819-6446-2019-15-2-251-257
Views:
859
Email this article 